CNBC's Jim Cramer breaks down why he's keeping an eye on shares of Bristol Myers. Irv Gotti, Music Producer and Murder Inc.

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Bristol Myers so ...

We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks. In this ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...

Bristol Myers Squibb stock tumbled Thursday on a light outlook for 2025 following a strong fourth-quarter report.

In his latest appearance on CNBC’s Squawk on the Street ... Eli Lilly, Amgen and Bristol Myers Squibb are included in this Analyst Blog. Novo Nordisk is under pressure from investors for ...

Bristol Myers walloped sales views Thursday, but Bristol Myers Squibb stock took a hit on a light outlook hamstrung by ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other stocks. Jim Cramer, the host of Mad Money, discussed the upcoming market and ...

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in ...

Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies. For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover ...